This application is a Continuation Application of Application Serial No. 09/357,704, filed on July 20, 1999; which is a Divisional of Application Serial No. 08/838,682, filed on April 9, 1997; which claims the benefit of U.S. Provisional Patent Application Serial No. 60/016,976, filed May 6, 1996, and U.S. Provisional Patent Application Serial No. 60/022,125, filed July 18, 1996.

IN THE CLAIMS:

Please cancel claims 1 - 67 from the prior application.

Please add the following claims 68 - 82:

68. An isolated antibody or binding portion thereof which competes with an antibody selected from the group consisting of E99, J415, J533 and J591 for binding to the extracellular domain of prostate specific membrane antigen.

69. The antibody or binding portion of claim 68, which is a monoclonal antibody or binding portion thereof.

70. The antibody or binding portion of claim 68, which is selected from the group consisting of a Fab fragment, a $F(ab)'_2$ fragment, and an Fv fragment.

71. The antibody or binding portion of claim 68, which is an IgG antibody.

72. The antibody or binding portion thereof of claim 68, which is bound to a drug.

73. The antibody or binding portion thereof of claim 72, wherein the drug is a cytotoxic drug.

74. The antibody or binding portion thereof of claim 73, wherein the cytotoxic drug is selected from the group consisting of a therapeutic drug, a compound emitting radiation, molecules of plant, fungal, or bacterial origin, biological protein, and mixtures thereof.

75. The antibody or binding portion thereof of claim 68, which is bound to a label.

76. The antibody or binding portion thereof of claim 73, wherein the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance label, a luminescent label, and a chromophore label.

77. A composition comprising the antibody or binding portion thereof of claim 68 or 72 and a physiologically acceptable carrier.

78. A composition comprising the antibody or binding portion thereof of claim 68 or 72 and a pharmaceutically acceptable carrier.

79. A kit for detecting prostate cancer comprising the antibody or binding portion thereof of claim 75 and means to detect the label.

80. A method of ablating or killing normal, benign hyperplastic, and cancerous prostate epithelial cells comprising contacting said cells with the antibody or binding portion thereof of claim 68 or 72 under conditions effective to permit ablating or killing of said cells.

81. The method of claim 76, wherein the contacting is carried out in a living mammal and comprises administering the antibody or binding portion thereof to the mammal under conditions effective to permit ablating or killing of said cells.

82. The method of claim 81, wherein the antibody or binding portion thereof is administered orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by intracavitory or intravesical instillation, intraarterially, intralesionally, or by application to mucous membranes.

Respectfully submitted,

LYON & LYON LLP

Dated: August 13, 2001

By: _____
Lois M. Kwasigroch
Reg. No. 35,579

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(213) 489-1600